The NHS Next Stage Review puts quality at the heart of everything that we do in the NHS, with the need to take an evidence based approach to avoid unnecessary reinvention of the wheel.

DAFNE has a solid evidence base. The programme has been developed over more than 25 years of rigorous research. This includes a randomised control trial in Northern Europe and a feasibility trial and economic analysis here in the UK. Please refer to Fact Sheet Two for further information on the evidence base.

The UK Feasibility study1 revealed that DAFNE led to significant improvements in glycaemic control, quality of life, psychological well being and treatment satisfaction.

An economic analysis performed by York Health Economics consortium (YHEC)2 revealed that DAFNE would pay for itself within 4-5 years due to the reduced complication rate expected due to improved glycaemic control.

The DAFNE Collaborative is committed to the continued improvement and development of DAFNE through Research and Development. The DAFNE programme provides a unique test-bed to conduct research not only to improve Type 1 diabetes management but also to learn more about educational interventions in diabetes and long-term conditions more generally.

Further information about current DAFNE research can be found in Fact Sheet Eleven.

 

DAFNE - delivering cost savings to the NHS

The Quality, Innovation, Productivity and Prevention (QIPP) collection on the NHS Evidence Database provides users and decision makers in the NHS with practical case studies that address the quality and productivity challenge in health and social care. All examples submitted are evaluated by NICE. Case studies are evaluated based on quality improvements, savings, evidence and implementation and are peer reviewed, with the top scoring (10%) case studies being recommended.

The DAFNE programme has been included as a QIPP case study since the database was launched in 2009. A recent update and review of the DAFNE case study by NICE has seen the programme retain it’s place on this database, demonstrating efficiency savings, estimated at £48 million per year nationally or £93,133 per 100,000 population, and improvements in quality. In addition the updated DAFNE case study has achieved recommended status.

The case study can be viewed on http://arms.evidence.nhs.uk/resources/qipp/899091/attachment; or alternatively to see the case study online, visit www.evidence.nhs.uk/qipp and click ‘what’s new’ and search the QIPP content by entering Type 1 diabetes in the search bar .

  1. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ: 2002; 325: 746
  2. Shearer A, Bagust A, Sanderson D, Heller S, Roberts S. Cost-effectiveness of flexible intensive insulin management to enable dietary freedom in people with Type 1 diabetes in the UK. Diabetic Medicine 2004; 21 (5):460-67

Last Updated: 30/01/2013